Nomura Asset Management Co. Ltd. Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Nomura Asset Management Co. Ltd. trimmed its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,547,095 shares of the company's stock after selling 77,747 shares during the quarter. Johnson & Johnson makes up 0.7% of Nomura Asset Management Co. Ltd.'s holdings, making the stock its 19th biggest position. Nomura Asset Management Co. Ltd. owned approximately 0.06% of Johnson & Johnson worth $223,741,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. IFS Advisors LLC boosted its stake in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the period. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $32,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the 3rd quarter worth approximately $35,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $38,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on JNJ shares. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research note on Monday, March 10th. Raymond James lowered their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Wells Fargo & Company cut their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Argus raised Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Finally, Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $171.33.

Remove Ads

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $2.13 during trading on Monday, hitting $165.84. 3,065,344 shares of the company's stock were exchanged, compared to its average volume of 9,000,967. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The business's 50-day simple moving average is $158.68 and its 200 day simple moving average is $156.07. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market cap of $399.64 billion, a price-to-earnings ratio of 24.94, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the business posted $2.29 earnings per share. The business's quarterly revenue was up 5.3% compared to the same quarter last year. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.